A total of 1 analyst ratings have been received for Sotera Health, with the consensus rating being Outperform. The average one-year price target stands at $13.0, suggesting a potential 17.54% upside.

AIS Healthcare has been awarded a group purchasing agreement for 503A intrathecal compounded medications with Premier, Inc., effective July 1, 2025. The new agreement allows Premier members, at their ...